Vicente Vérez-Bencomo

Author

Also Known As

Bencomo, Vicente Verez, V Verez Bencomo, V. V. BENCOMO, V. VEREZ BENCOMO, V. VEREZ‐BENCOMO, V. Verez Bencomo, V. Verez-Bencomo, V. Verez-bencomo, V. Vérez-Bencomo, Vicente G. Vérez-Bencomo

125

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Finlay Institute University of Havana Center of Molecular Immunology (Cuba)Instituto de Medicina Tropical “Pedro Kourí”Cuban Neuroscience Center

About

Vicente Vérez-Bencomo is an author at Finlay Institute specializing in medicine, glycobiology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	22	1.1K
2	Natural Sciences	10	10	179
3	Engineering	4	4	80
4	Public Health	1	1	11
5	Allergy	1	1	39

Vicente Vérez-Bencomo

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
A Synthetic Conjugate Polysaccharide Vaccine Against <i>Haemophilus influenzae</i> Type b Vicente Vérez-Bencomo, Violeta Fernández-Santana, Eugenio Hardy, Science VaccinationCross-protectionHib PolysaccharideVaccine DevelopmentMedicine	2004	481
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies Yury Valdés-Balbín, Darielys Santana-Mederos, Lauren Quintero, ACS Chemical Biology VaccinationVaccine DevelopmentVirus InfectionPreclinical StudiesVaccine Target	2021	88
Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota Fabrizio Chiodo, Sven C. M. Bruijns, Ernesto Rodríguez, Host Lung MicrobiotaViral PathogenesisGlycobiologyImmunologyImmunodominance	2020	81
Effect of shape, size, and valency of multivalent mannosides on their binding properties to phytohemagglutinins René Roy, Daniel Pagé, Santiago Figueroa Pérez, Glycoconjugate Journal	1998	73
Synthetic, Zwitterionic Sp1 Oligosaccharides Adopt a Helical Structure Crucial for Antibody Interaction Qingju Zhang, Ana Gimeno, Darielys Santana-Mederos, ACS Central Science	2019	69
Multicomponent polysaccharide–protein bioconjugation in the development of antibacterial glycoconjugate vaccine candidates Yanira Méndez, Janoi Chang, Ana R. Humpierre, Chemical Science	2018	53
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva, The Lancet Regional Health - Americas	2022	44
Bioengineered polyester beads co-displaying protein and carbohydrate-based antigens induce protective immunity against bacterial infection Majela González-Miró, Laura Rodríguez-Noda, Mildrey Fariñas-Medina, Scientific Reports	2018	42
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial Arturo Chang Monteagudo, Rolando Ochoa-Azze, Yanet Climent-Ruíz, The Lancet Regional Health - Americas	2021	40
Antigenicity and Immunogenicity of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against <i>Haemophilus influenzae</i> Type b Violeta Fernández-Santana, Félix Cardoso, Arlene Rodríguez, Infection and Immunity VaccinationCross-protectionVaccine ProductionVaccine DevelopmentAllergy	2004	39

Page 1